X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Adzynma (apadamtase alfa /cinaxadamtase alfa) is the first and only recombinant ADAMTS13 enzyme replacement therapy, which is approved for the treatment of congenital thrombotic thrombocytopenic purpura in patients 12 years of age and older.
Lead Product(s): Apadamtase Alfa,Cinaxadamtase Alfa
Therapeutic Area: Rare Diseases and Disorders Product Name: Adzynma
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Protagonist Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Iclusig (ponatinib) is a kinase inhibitor targeting BCR::ABL1. It is approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
Lead Product(s): Ponatinib
Therapeutic Area: Oncology Product Name: Iclusig
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Iclusig (ponatinib), a Tyrosine kinase inhibitor receives Supplemental New Drug Application approval by the U.S. FDA. It is indicated for the treatment of adult patients with Ph+ Acute Lymphoblastic Leukemia.
Lead Product(s): Ponatinib
Therapeutic Area: Oncology Product Name: Iclusig
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
The collaboration aims to support the development of PTG-300 (rusfertide) for the treatment of Polycythemia Vera. The protagonist will be responsible for research and development through the completion of the Phase 3 clinical trial and U.S. regulatory approval.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Protagonist Therapeutics
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration March 18, 2024
Details:
TAK-079 (mezagitamab) is a fully human immunoglobulin IgG1 monoclonal antibody (mAb) with high affinity for CD38 expressing cells resulting in their depletion. It is being developed for patients with persistent or chronic primary immune thrombocytopenia (ITP).
Lead Product(s): Mezagitamab
Therapeutic Area: Immunology Product Name: TAK-079
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
The collaboration will assist Biological E in both manufacturing and commercializing Qdenga (live attenuated tetravalent dengue vaccine). This vaccine is intended for the treatment of individuals afflicted with Dengue fever.
Lead Product(s): Live Attenuated Tetravalent Dengue Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Qdenga
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Biological E
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2024
Details:
Eohilia (budesonide) is an oral suspension, glucocorticoid receptor agonist, which is approved by USFDA for the treatment of Eosinophilic Esophagitis (EoE).
Lead Product(s): Budesonide
Therapeutic Area: Gastroenterology Product Name: Eohilia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
TAK-861 is an oral orexin agonist which is being evaluated in phase 2/3 clinical trials for the treatment of patients with Narcolepsy Type 1 & Type 2.
Lead Product(s): TAK-861
Therapeutic Area: Sleep Product Name: TAK-861
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
The collaboration aims to support the development of PTG-300 (rusfertide) for the treatment of Polycythemia Vera. The protagonist will be responsible for research and development through the completion of the Phase 3 clinical trial and U.S. regulatory approval.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Protagonist Therapeutics
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration January 31, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
